Case Report: Specific ABL-Inhibitor Imatinib Is an Effective Targeted Agent as the First Line Therapy to Treat B-Cell Acute Lymphoblastic Leukemia With a Cryptic NUP214::ABL1 Gene Fusion

Overview of attention for article published in Pathology & Oncology Research, September 2022

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (53rd percentile)
High Attention Score compared to outputs of the same age and source (80th percentile)

So far, Dimensions has found 2 publications that cite this research output.

Article in Reactions Weekly (March 2023)

Article in Pediatric Blood & Cancer (January 2023)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.